Patents Assigned to Johann Wolfgang Goethe-Universitat
-
Publication number: 20240025926Abstract: The present invention relates to a compound of formula (I) wherein E1 to E6 are independently Si or Ge; X1 to X4 are independently selected from the group consisting of H, SiH3, halogen and Si(Y)3; Y is independently selected from C1 to C20 alkyl and halogen; R1 to R12 are independently selected from the group consisting of C1 to C20 alkyl, C2 to C20 alkenyl, C2 to C20 alkynyl, C3 to C20 cycloalkyl, C6 to C20 aryl, C7 to C20 arylalkyl, C7 to C20 alkylaryl and Z; and Z is independently selected from the group consisting of H, halogen and C1 to C20 alkyl; a process for their preparation; and the use of the compound for preparing the Si- and Ge-containing solid.Type: ApplicationFiled: November 18, 2021Publication date: January 25, 2024Applicant: Johann Wolfgang Goethe-UniversitätInventors: Matthias WAGNER, Benedikt KÖSTLER, Hans-Wolfram LERNER
-
Publication number: 20230407263Abstract: The present invention pertains to an improved mesenchymal stromal cell (MSC) preparation and a method for producing the same. The invention provides a new strategy to isolate MSC from bone marrow mononuclear cells (BM-MNCs) by pooling BM-MNCs of multiple unrelated (third-party) bone marrow donors. The MSC preparation manufactured in accordance with the methodology of the invention is characterized by a stable proliferative capability and an increased immunosuppressive potential when compared to individual donor MSC preparations or a pool of individual MSCs generated from multiple donors. The MSCs prepared according to the invention are particularly useful for medical applications such as the treatment of graft-versus-host disease (GvHD) in recipients with hematopoietic stem cell transplants, patients with autoimmune disorders and as a cell-based therapy in regenerative medicine.Type: ApplicationFiled: February 2, 2023Publication date: December 21, 2023Applicants: Johann Wolfgang Goethe-Universität, Frankfurt Am Main, DRK BLUTSPENDEDIENST BADEN-WÜRTTEMBERG-HESSEN GGMBHInventors: Peter Bader, Selim Kuci, Zyrafete Kuci, Halvard Bönig
-
Publication number: 20230365673Abstract: The invention is based on the modulation of cancer-associated fibroblasts (CAFs) in the treatment of proliferative disorders by radiotherapy. By reducing CAF sensitivity to cellular senescence adverse immune reactions upon radiotherapy of solid tumours and subsequent treatment resistance could be avoided. The invention pertains to senolytics or Interleukin 1 (IL1) signalling inhibitors for use in a method of treating solid tumours and in the treatment or prevention of inflammatory adverse effects upon radiation therapy in context of a cancer treatment. The invention optionally also pertains to senolytics or Interleukin 1 (IL1) signalling inhibitors for use in a method of treating solid tumours and in the treatment or prevention of inflammatory adverse effects upon chemotherapy and/or radiation therapy in context of a cancer treatment.Type: ApplicationFiled: September 15, 2021Publication date: November 16, 2023Applicants: JOHANN WOLFGANG GOETHE-UNIVERSITÄT FRANKFURT AM MAIN, CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT GEORG-SPEYER-HAUSInventors: Florian GRETEN, Adele NICOLAS, Claus RÖDEL, Emmanouil FOKAS
-
Publication number: 20230265439Abstract: The present invention relates to a combination of inhibitory nucleic acid agents directed at a combination of transcription factors for treatment of heart failure. The combination of inhibited transcription factors comprises one of the groups selected from RARa, TCF7L2, E2F6 and LEF1, or RARa, TCF7L2, E2F7 and NFYb. The combinatorial inhibition of these transcription factors is shown to increase cardiomyocyte proliferation.Type: ApplicationFiled: July 23, 2021Publication date: August 24, 2023Applicant: JOHANN WOLFGANG GOETHE-UNIVERSITÄT FRANKFURTInventors: Jaya KRISHNAN, Ting YUAN
-
Publication number: 20230265426Abstract: The present invention relates to a combination of inhibitory nucleic acid agents directed at a combination of miRNAs for treatment of heart failure. The combination of inhibited miRNAs comprises one of the groups selected from miR-1a, and miR-15b, or miR-1a, miR-15b and miR-27b, or miR-1a, miR-27b and miR-34a. The combinatorial inhibition of these miRNAs is shown to increase cardiomyocyte proliferation.Type: ApplicationFiled: July 23, 2021Publication date: August 24, 2023Applicant: JOHANN WOLFGANG GOETHE-UNIVERSITÄT FRANKFURTInventors: Jaya KRISHNAN, Ting YUAN, Stefanie DIMMELER
-
Patent number: 11643643Abstract: The present invention pertains to a novel architecture of non-ribosomal peptide synthases (NRPS). The invention provides artificial NRPS wherein the naturally occurring terminal condensation or thioesterase-domain is replaced by internal condensation or dual condensation/epimerization domains. Moreover, the present invention enables the portability of terminal condensation domains to unrelated NRPS in respect of peptide release of linear peptides. The replacement results in a product independent release of the synthesized product and therefore enables the rational design of NRPS. The invention provides the new NRPS, nucleic acids encoding them, methods for artificial NRPS generation, and methods for producing non-ribosomal peptides.Type: GrantFiled: February 8, 2017Date of Patent: May 9, 2023Assignee: Johann Wolfgang Goethe-Universität Frankfurt am MainInventors: Helge B. Bode, Kenan Bozhüyük, Florian Fleischhacker
-
Publication number: 20220403363Abstract: The invention relates to a system for expressing nonribosomal peptide synthetases (NRPSs), polyketide synthases (PKS) or NRPS/PKS hybrid synth(et)ases. NRPS, PKS or hybrids thereof are large multi-domain proteins or multi-domain complexes, the expression of which for the production of peptides often causes difficulties. The invention correspondingly relates to a system for expressing portions of the enzymes which can be assembled post-translationally via protein-protein interactions, introduced in a targeted manner, to form multi-enzyme complexes. The invention discloses protein fragments of such an assembly, and the nucleic acids coding therefor. The invention also relates to a vector system for the protein fragments of the invention and its use for producing functional NRPS/PKS enzyme complexes.Type: ApplicationFiled: November 12, 2020Publication date: December 22, 2022Applicant: JOHANN WOLFGANG GOETHE-UNIVERSITÄT FRANKFURT AM MAINInventors: Helge BODE, Kenan BOZHÜYÜK, Jonas WATZEL
-
Patent number: 11473078Abstract: The present invention concerns a novel method for the modification and/or custom-made design of artificial non-ribosomal peptide synthetases (NRPSs) from naturally available NRPSs. The artificial NRPSs are of predetermined length and amino acid composition and sequence. Via fusion of well-defined NRPS units (so-called “exchange units”) in a certain manner, using a specific sequence motif in the linker areas it is possible to construct artificial and/or modified NRPS assembly lines, which have the ability of synthesizing peptides of a desired structure.Type: GrantFiled: July 6, 2016Date of Patent: October 18, 2022Assignee: JOHANN WOLFGANG GOETHE-UNIVERSITATInventors: Claus-Peter Niesert, Helge B. Bode, Kenan Bozhueyuek, Florian Fleischhacker
-
Patent number: 11447445Abstract: N-benzylbenzamides that act as dual soluble epoxide hydrolase (sEH)/peroxisome proliferator-activated receptor ? (PPAR?) modulators and are useful as medications in the treatment of Metabolic Syndrome (MetS) cluster diseases, including diabetes. Methods of making and using the same are further provided.Type: GrantFiled: December 23, 2020Date of Patent: September 20, 2022Assignees: The Medical College of Wisconsin, Inc., Johann Wolfgang Goethe-Universität FrankfurtInventors: John David Imig, Md. Abdul Hye Khan, Eugen Proschak, Rene Blocher
-
Publication number: 20220194943Abstract: Ephrin type receptor tyrosine kinase inhibitors, also known as Eph tyrosine kinase receptor inhibitors, for treating cancer, an inflammatory disease, an autoimmune disease, or a degenerative disease characterized at least in part by the abnormal activity or expression of the Eph receptor tyrosine kinase. The inhibitors are particularly useful for treating certain cancers.Type: ApplicationFiled: March 11, 2022Publication date: June 23, 2022Applicants: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Servic, Johann Wolfgang Goethe-Universität, Deutsches KrebsforschungszentrumInventors: Giovanna Tosato, Michael J. DiPrima, Harald Schwalbe, Alix Tröster, Denis Kudlinzki, Nathalie Jores
-
Publication number: 20210261954Abstract: The present invention pertains to a novel method for the generation of a vector construct suitable for gene editing applications which comprises a fixed pair of predetermined expressible guide RNA (gRNA) sequences. The method of the invention allows for an easy construction of such vectors and provides in addition thereto vector libraries for the expression of fixed pairs of gRNAs. The vectors of the invention may be advantageously used to cut out larger genomic DNA sequences, or alternatively, to simultaneously introduce mutations in the genome without a loss or larger genomic sequences. Hence, the system of the invention provides for many molecular genetic approaches for genome alteration.Type: ApplicationFiled: June 11, 2019Publication date: August 26, 2021Applicant: Johann Wolfgang Goethe-Universitat Frankfurt am MainInventors: Manuel Kaulich, Ivan Dikic, Martin Wegner, Yves Matthess, Koraljka Husnjak
-
Publication number: 20210238125Abstract: N-benzylbenzamides that act as dual soluble epoxide hydrolase (sEH)/peroxisome proliferator-activated receptor ? (PPAR?) modulators and are useful as medications in the treatment of Metabolic Syndrome (MetS) cluster diseases, including diabetes. Methods of making and using the same are further provided.Type: ApplicationFiled: December 23, 2020Publication date: August 5, 2021Applicants: The Medical College of Wisconsin, Inc., Johann Wolfgang Goethe-Universität FrankfurtInventors: John David Imig, Md. Abdul Hye Khan, Eugen Proschak, Rene Blocher
-
Patent number: 11078468Abstract: The present invention relates to proteins involved in fatty acid synthesis, such as fatty acid synthases (FAS) variants, comprising one or more polypeptide chains, wherein said polypeptide chain(s) comprise one or more subunits comprising a malonyl/palmitoyl transferase domain (MPT domain), acetyl transferase domain (AT domain), and ketoacyl synthase domain (KS domain), and at least one amino acid substitution in the MPT domain at a position corresponding to R130, in the AT domain at a position corresponding to I306, and/or in the KS domain, preferably in the acyl binding channel and/or at KS domain binding site to ACP, to modulate affinities of acyl intermediates, and optionally further amino acid substitution(s). The present invention relates to the respective polypeptide domains. The present invention further relates to nucleic acid molecules encoding the proteins (or the polypeptide domains) and to host cells containing said nucleic acid molecules.Type: GrantFiled: March 31, 2016Date of Patent: August 3, 2021Assignee: Johann Wolfgang Goethe-Universität Frankfurt am MainInventors: Martin Grininger, Jan Gajewski, Eckhard Boles, Renata Pavlovic
-
Patent number: 10927069Abstract: N-benzylbenzamides that act as dual soluble soluble epoxide hydrolase (sEH)/peroxisome proliferator-activated receptor ? (PPAR?) modulators and are useful as medications in the treatment of Metabolic Syndrome (MetS) cluster diseases, including diabetes. Methods of making and using the same are further provided.Type: GrantFiled: July 1, 2016Date of Patent: February 23, 2021Assignees: The Medical College of Wisconsin, Inc., Johann Wolfgang Goethe-Universitat FrankfurtInventors: John David Imig, Md. Abdul Hye Khan, Eugen Proschak, Rene Blocher
-
Patent number: 10717997Abstract: The present invention relates to a method for storing gaseous hydrogen, comprising the steps of producing methanoate (formate) through contacting gaseous hydrogen with carbon dioxide in the presence of a hydrogen dependent carbon dioxide reductase (HDCR), and thereby storing of said gaseous hydrogen. The HDCR and/or its complex is preferably derived from Acetobacterium woodii.Type: GrantFiled: June 26, 2018Date of Patent: July 21, 2020Assignee: JOHANN WOLFGANG GOETHE-UNIVERSITÄTInventors: Volker Müller, Kai Schuchmann
-
Publication number: 20180297936Abstract: A catheter assembly includes an elongated catheter shaft, a magnetic sensor, and one or more wires. The elongated catheter shaft has a shaft proximal end and a shaft distal end, and the magnetic sensor includes a coil having a coil proximal end and a coil distal end that is situated toward or at the shaft distal end. The one or more wires extend through the elongated catheter shaft and are situated adjacent the magnetic sensor. Each of the one or more wires is electrically coupled to the coil at the coil distal end.Type: ApplicationFiled: July 1, 2016Publication date: October 18, 2018Applicants: The Medical College of Wisconsin, Inc., Johann Wolfgang Goethe-Universität FrankfurtInventors: John David Imig, Md. Abdul Hye Khan, Eugen Proschak, Rene Blocher
-
Patent number: 10036045Abstract: The present invention relates to a method for storing gaseous hydrogen, comprising the steps of producing methanoate (formate) through contacting gaseous hydrogen with carbon dioxide in the presence of a hydrogen dependent carbondioxide reductase (HDCR), and thereby storing of said gaseous hydrogen. The HDCR and/or its complex is preferably derived from Acetobacterium woodii.Type: GrantFiled: June 18, 2014Date of Patent: July 31, 2018Assignee: JOHANN WOLFGANG GOETHE-UNIVERSITÄTInventors: Volker Müller, Kai Schuchmann
-
Patent number: 9655947Abstract: The invention relates to the use of a granulin or a granulin-like compound for producing a pharmaceutical composition for the therapy or prophylaxis of chronic pain, in particular for neuropathic pain.Type: GrantFiled: December 28, 2012Date of Patent: May 23, 2017Assignee: JOHANN WOLFGANG GOETHE-UNIVERSITAT FRANKFURT AM MAINInventors: Irmgard Tegeder, Gerd Geisslinger
-
Patent number: 9606114Abstract: New compounds of the general formula Xm-G-CLn are described as well as methods for their production and use in the analysis, detection and purification of target molecules. These constitute multivalent chelator-compounds with an affinity-tag binding to metal-chelator-complexes which can selectively modify and/or immobilize target molecules by a multitude of probes or functional units.Type: GrantFiled: July 26, 2005Date of Patent: March 28, 2017Assignee: JOHANN WOLFGANG GOETHE-UNIVERSITAT FRANKFURT AM MAINInventors: Jacob Piehler, Robert Tampe, Suman Lata
-
Patent number: 9554726Abstract: A hyperpolarized liquid contrast agent is for use in a MRT device. The liquid contrast agent passes through a conduit of a MW resonator in the magnetic field of the MRT device. A microwave with a frequency of at least 40 GHz couples into the MW resonator for polarizing the liquid contrast agent upon passage through the conduit in the MW resonator using DNP. The contrast agent is polarized in a continuous passage in the MW resonator and administered immediately. A MW mode is formed in the MW resonator which has an antinode in the magnetic field strength and a node in the electric field strength. The power of the introduced microwave and coupling of the microwave into the resonator are adjusted such that in the area of the line, an amplitude of the MW magnetic field strength B 1 ? 1.5 · 10 - 2 ? Ts ? 1 T 1 , e results, wherein T1,e is the relaxation time of the DNP-active electrons.Type: GrantFiled: December 20, 2012Date of Patent: January 31, 2017Assignee: Johann Wolfgang Goethe-Universität Frankfurt am MainInventors: Jan Krummenacker, Thomas Prisner, Vasyl Denysenkov, Laura Schreiber, Kerstin Münnemann